Changes to the Code
H.R. 1492 · To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 1320f–1 Selection of negotiation-eligible drugs as selected drugs
+1 −1Shown
1 change the bill asks for here, 1 carried out
- Carried out:
Section 1192(e)(1)(A)(ii) of the Social Security Act (42 U.S.C. 1320f–1(e)(1)(A)(ii)) is amended by striking
7 years
and inserting11 years
.
§ 1320f–1(e)(1)In general(A)–(B)
Start of § 1320f–1 to (e)(1)(A) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (A)(i) | (i) | (i) | ||
| that is approved under section 355(c) of title 21 and is marketed pursuant to such approval; | that is approved under section 355(c) of title 21 and is marketed pursuant to such approval; | |||
| (A)(ii) | (ii) | (ii) | ||
| for which, as of the selected drug publication date with respect to such initial price applicability year, at least | for which, as of the selected drug publication date with respect to such initial price applicability year, at least [inserted: 11] years will have elapsed since the date of such approval; and | |||
| (A)(iii) | (iii) | (iii) | ||
| that is not the listed drug for any drug that is approved and marketed under section 355(j) of such title. | that is not the listed drug for any drug that is approved and marketed under section 355(j) of such title. | |||
| (B) | (B) Biological products | (B) Biological products | ||
| A biological product— | A biological product— |
Rest of § 1320f–1 unchanged